1. Transdermal Patch Medical Device
2. Intrauterine Device

Global Transdermal Patch Market: This market research report focuses on Past-Current Size, Shares, Trends, Price, Segmentation and Forecast 2017-2022. Global Transdermal Patch Market: This market research report focuses on Past-Current Size, Shares, Trends, Price, Segmentation and Forecast 2017-2022. Exelon Patch from Novartis India, Rivastigmine - Exelon to Zeemine Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for. Sparsha Pharma International Pvt. Was established in 2008 as the first transdermal company in India to engage in R&D, manufacturing and marketing of transdermal.

Rusan's fentanyl-delivering patch Fenstud-Courtesy of Rusan Mumbai, India's Rusan Pharma just inaugurated a $15 million facility dedicated to researching and manufacturing drug-delivering transdermal patches in Gujarat's Kandla special economic zone, dubbed the Navin Saxena Research and Technology center. The company makes the Fenstud fentanyl opioid pain patch, along with variety of other sublingual, oral and injectable meds.

Therapeutic areas to be targeted at the NSRT include pain, addiction, central nervous system conditions and orphan diseases. Drug delivery and platform technologies will also be studied, reports Indian news outlet, The Economic Times. 'Through this new facility, India can enter the innovation drive for the niche categories targeted by NSRT as a participation of $375 million global licensing market,' Rusan Pharma chairman Navin Saxena said, according to The Economic Times. In addition, the company announced an agreement to supply the Brazilian Health Ministry with its smoking cessation drug. 'With our efforts and innovation, we announce the biggest government and private Indian company deal between Brazil Health Ministry & Rusan Pharma for USD 20 million per annum. The company's '2baconil' drug will be used for the Brazilian government's program for smoking cessation,' Saxena said in the article. According to the company website, Rusan Pharma acquired a Novartis ($NVS) factory in the special economic zone in 2000, and opened a formulation facility there in 2002.

But European inspectors just reported 'a widespread failure of the Quality Management System' at a Rusan facility in the Kandla special economic zone. In 2012, the U.K. Banned at least 20 drugs manufactured at the plant. The sanction will continue.

Chapter 1: World’s First Transdermal Patch for Treatment of Asthma The Hokunalin® Tape jointly developed in 1988 by Abbott Japan Co., Ltd and Nitto Denko was the world's first transdermal patch for treatment of asthma. The adhesive layer of the tape contains tulobuterol, a drug that dilates the bronchial tubes making it easier for asthma sufferers to breathe. When the patch is applied to the skin, the drug penetrates the skin and is absorbed into the blood stream through the capillaries to flow throughout the body. This is in effect the same as using an injection, but without requiring the use of a needle. Unlike conventional oral and inhaled formulations, Hokunalin® Tape has the advantage of being able to appropriately control the concentration of the drug in the body. This means that users can control asthma attacks, which frequently occur in the early morning, and that the burden on caregivers is also greatly reduced. The development of these patches, however, took 11 years and was full of challenges.

The mechanism whereby drugs are delivered to the body through the transdermal patch. Designing transdermal patches is one area in which Nitto Denko has a great deal of expertise.

By 1983 we had already developed a transdermal patch for preventing the onset of angina. With conventional transdermal formulations, drugs were continuously in the body for long periods of time. The developers wanted to develop a more advanced product that was able to deliver the required drug dosage at the right time for use in the treatment of asthma. In many cases, asthma attacks occur at set times, such as in the early morning. If a drug delivery system could be developed that was able to deliver the optimum amount of medication at that time (a smart drug delivery system), then it would be possible to dramatically increase the quality of life of asthma sufferers.

Transdermal Patch Medical Device

In order to realize this goal, however, it is necessary to achieve precision control of drug release speed. This proved to be extremely difficult. Chapter 3: Tenacity was required to Solve the Problem of Drug Content and Concentration Control Drug release speed is determined by the complex relationships between the type of adhesive used, the thickness of the adhesive coating, and the content and concentration of drug contained in the adhesive. Moreover, the type of adhesive that can be used in medical applications is also limited, which means that inevitably it is necessary to control release speed using drug content and concentration. In the absence of any revolutionary way of solving this problem, it was a matter of making samples with various combinations in a process of trial and error. Although computer simulations can now be used for parts of this process, at that particular time there was no such convenience.

It was a case of trying every combination and investigating each individual possibility. Eventually, as a result of many years of painstaking hard work, this goal was achieved by utilizing a mechanism whereby some of the drug in the adhesive was maintained in a crystalline state while the rest was kept in a dissolved state. This proprietary technology was subsequently applied in the manufacture of other adhesive tapes.

In order to commercialize this product, however, the company first had to develop advanced processing technology. In the transdermal patch manufacturing process, it was necessary to maintain the thickness of the adhesive layer at µ20 (0.02mm). Because the product was to be used in medical applications there could be no variation in quality and at the time of manufacture it was necessary to control tape thickness to within ±2µm (0.002mm). It is no exaggeration to say that precision coating technology is the real secret behind the successfully commercialization of this product. Chapter 4: You'll Never Succeed Unless You Try In order to achieve goals it is necessary to think a lot and then to translate the ideas that come into action, and to repeat this process time and time again. Basically, manufacturing is a process that requires you to get your hands dirty and involves much sweat and tears. There is nothing glamorous about it at all.

That is probably one of the reasons that success, when it eventually comes, is particularly sweet. At times it may seem as though you are facing a brick wall, but when you get off course you just have to take the initiative and try something else. Nothing gets solved sitting at a desk.

Intrauterine Device

World-first products do not suddenly appear as a result of some revolutionary idea. The development of Hokunalin® Tape teaches us much about the importance of continually trying out various ideas and combinations.